Pityriasis Simplex — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for pityriasis simplex. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
4
Active US patents
72/100
Avg vulnerability
—
Annual revenue covered

Originators in Pityriasis Simplex

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Eurofarma 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating pityriasis simplex. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
27
2
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Derma-Smoothe/Fs
FLUOCINOLONE ACETONIDE
 Eurofarma 4 72 — 2027-08-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9849027 Derma-Smoothe/Fs method of use 88 2028-11-07
7998108 Derma-Smoothe/Fs method of use 83 2028-01-12
8871241 Derma-Smoothe/Fs formulation 60 2027-08-12
8871241 Derma-Smoothe/Fs formulation 55 2027-08-12

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8871241 Derma-Smoothe/Fs formulation 55 2027-08-12
8871241 Derma-Smoothe/Fs formulation 60 2027-08-12
7998108 Derma-Smoothe/Fs method of use 83 2028-01-12
9849027 Derma-Smoothe/Fs method of use 88 2028-11-07

Related